Ribavirin (English Wikipedia)

Analysis of information sources in references of the Wikipedia article "Ribavirin" in English language version.

refsWebsite

Global rank English rank

76nih.gov

4^th place

53doi.org

2^nd place

15semanticscholar.org

11^th place

8^th place

10web.archive.org

1^st place

6harvard.edu

18^th place

17^th place

2drugs.com

399^th place

333^rd place

2handle.net

102^nd place

76^th place

2fda.gov

447^th place

338^th place

1in.gov.br

3,151^st place

5,932^nd place

1catie.ca

low place

1tga.gov.au

3,984^th place

2,622^nd place

1books.google.com

3^rd place

1medscape.com

719^th place

636^th place

1rki.de

4,845^th place

low place

1njmonline.nl

low place

1cdc.gov

218^th place

212^th place

1news-medical.net

8,069^th place

7,681^st place

1researchgate.net

120^th place

125^th place

1clinicaltrials.gov

5,225^th place

4,062^nd place

books.google.com

Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 504. ISBN 9783527607495. Archived from the original on 2016-12-20.

catie.ca

"Ribavirin (Ibavyr)". Catie. 2022. Retrieved 22 August 2022.

cdc.gov

"Treatment | Lassa Fever | CDC". 2023-09-26. Archived from the original on 2023-09-26. Retrieved 2024-01-20.

clinicaltrials.gov

U.S. National Library of Medicine (2012-06-22). Study of Viramidine to Ribavirin in Patients With Chronic Hepatitis C Who Are Treatment Naive (VISER2) (Report). National Institutes of Health. Retrieved 2021-03-25.

doi.org

Paeshuyse J, Dallmeier K, Neyts J (December 2011). "Ribavirin for the treatment of chronic hepatitis C virus infection: a review of the proposed mechanisms of action". Current Opinion in Virology. 1 (6): 590–598. doi:10.1016/j.coviro.2011.10.030. PMID 22440916.
Flori N, Funakoshi N, Duny Y, Valats JC, Bismuth M, Christophorou D, et al. (March 2013). "Pegylated interferon-α2a and ribavirin versus pegylated interferon-α2b and ribavirin in chronic hepatitis C : a meta-analysis". Drugs. 73 (3): 263–277. doi:10.1007/s40265-013-0027-1. PMID 23436591. S2CID 46334977.
Druyts E, Thorlund K, Wu P, Kanters S, Yaya S, Cooper CL, et al. (April 2013). "Efficacy and safety of pegylated interferon alfa-2a or alfa-2b plus ribavirin for the treatment of chronic hepatitis C in children and adolescents: a systematic review and meta-analysis". Clinical Infectious Diseases. 56 (7): 961–967. doi:10.1093/cid/cis1031. PMID 23243171.
Zeuzem S, Poordad F (July 2010). "Pegylated-interferon plus ribavirin therapy in the treatment of CHC: individualization of treatment duration according to on-treatment virologic response". Current Medical Research and Opinion. 26 (7): 1733–1743. doi:10.1185/03007995.2010.487038. PMID 20482242. S2CID 206965239.
Zhu Q, Li N, Han Q, Zhang P, Yang C, Zeng X, et al. (June 2013). "Statin therapy improves response to interferon alfa and ribavirin in chronic hepatitis C: a systematic review and meta-analysis". Antiviral Research. 98 (3): 373–379. doi:10.1016/j.antiviral.2013.04.009. PMID 23603497.
Chung RT, Ghany MG, Kim AY, Marks KM, Naggie S, Vargas HE, et al. (AASLD-IDSA HCV Guidance Panel) (October 2018). "Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection". Clinical Infectious Diseases. 67 (10): 1477–1492. doi:10.1093/cid/ciy585. PMC 7190892. PMID 30215672.
Pawlotsky J, Negro F, Aghemo A, Berenguer M, Dalgard O, Dusheiko G, et al. (August 2018). "EASL Recommendations on Treatment of Hepatitis C 2018". Journal of Hepatology. 69 (2): 461–511. doi:10.1016/j.jhep.2018.03.026. PMID 29650333.
Ascioglu S, Leblebicioglu H, Vahaboglu H, Chan KA (June 2011). "Ribavirin for patients with Crimean-Congo haemorrhagic fever: a systematic review and meta-analysis". The Journal of Antimicrobial Chemotherapy. 66 (6): 1215–1222. doi:10.1093/jac/dkr136. PMID 21482564.
Bausch DG, Hadi CM, Khan SH, Lertora JJ (December 2010). "Review of the literature and proposed guidelines for the use of oral ribavirin as postexposure prophylaxis for Lassa fever". Clinical Infectious Diseases. 51 (12): 1435–1441. doi:10.1086/657315. PMC 7107935. PMID 21058912.
Soares-Weiser K, Thomas S, Thomson G, Garner P (July 2010). "Ribavirin for Crimean-Congo hemorrhagic fever: systematic review and meta-analysis". BMC Infectious Diseases. 10: 207. doi:10.1186/1471-2334-10-207. PMC 2912908. PMID 20626907.
Ventre K, Randolph AG (January 2007). Ventre K (ed.). "Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children". The Cochrane Database of Systematic Reviews (1): CD000181. doi:10.1002/14651858.CD000181.pub3. PMID 17253446.
Hemachudha T, Ugolini G, Wacharapluesadee S, Sungkarat W, Shuangshoti S, Laothamatas J (May 2013). "Human rabies: neuropathogenesis, diagnosis, and management". The Lancet. Neurology. 12 (5): 498–513. doi:10.1016/S1474-4422(13)70038-3. PMID 23602163. S2CID 1798889.
Elia G, Belloli C, Cirone F, Lucente MS, Caruso M, Martella V, et al. (February 2008). "In vitro efficacy of ribavirin against canine distemper virus". Antiviral Research. 77 (2): 108–113. doi:10.1016/j.antiviral.2007.09.004. PMID 17949825.
Baker RO, Bray M, Huggins JW (January 2003). "Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections". Antiviral Research. 57 (1–2): 13–23. doi:10.1016/S0166-3542(02)00196-1. PMC 9533837. PMID 12615299.
Bierman SM, Kirkpatrick W, Fernandez H (1981). "Clinical efficacy of ribavirin in the treatment of genital herpes simplex virus infection". Chemotherapy. 27 (2): 139–145. doi:10.1159/000237969. PMID 7009087.
Pancheva SN (September 1991). "Potentiating effect of ribavirin on the anti-herpes activity of acyclovir". Antiviral Research. 16 (2): 151–161. doi:10.1016/0166-3542(91)90021-I. PMID 1665959.
Kast RE (November–December 2002). "Ribavirin in cancer immunotherapies: controlling nitric oxide helps generate cytotoxic lymphocyte". Cancer Biology & Therapy. 1 (6): 626–630. doi:10.4161/cbt.310. PMID 12642684. S2CID 24010404.
Borden KL, Culjkovic-Kraljacic B (October 2010). "Ribavirin as an anti-cancer therapy: acute myeloid leukemia and beyond?". Leukemia & Lymphoma. 51 (10): 1805–1815. doi:10.3109/10428194.2010.496506. PMC 2950216. PMID 20629523.
Dunn LA, Fury MG, Sherman EJ, Ho AA, Katabi N, Haque SS, et al. (February 2018). "Phase I study of induction chemotherapy with afatinib, ribavirin, and weekly carboplatin and paclitaxel for stage IVA/IVB human papillomavirus-associated oropharyngeal squamous cell cancer". Head & Neck. 40 (2): 233–241. doi:10.1002/hed.24938. PMC 6760238. PMID 28963790.
Burman B, Drutman SB, Fury MG, Wong RJ, Katabi N, Ho AL, et al. (May 2022). "Pharmacodynamic and therapeutic pilot studies of single-agent ribavirin in patients with human papillomavirus-related malignancies". Oral Oncology. 128: 105806. doi:10.1016/j.oraloncology.2022.105806. PMC 9788648. PMID 35339025.
Assouline S, Culjkovic B, Cocolakis E, Rousseau C, Beslu N, Amri A, et al. (July 2009). "Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin". Blood. 114 (2): 257–260. doi:10.1182/blood-2009-02-205153. PMID 19433856. S2CID 28957125.
Assouline S, Culjkovic-Kraljacic B, Bergeron J, Caplan S, Cocolakis E, Lambert C, et al. (January 2015). "A phase I trial of ribavirin and low-dose cytarabine for the treatment of relapsed and refractory acute myeloid leukemia with elevated eIF4E". Haematologica. 100 (1): e7–e9. doi:10.3324/haematol.2014.111245. PMC 4281321. PMID 25425688.
Assouline S, Gasiorek J, Bergeron J, Lambert C, Culjkovic-Kraljacic B, Cocolakis E, et al. (March 2023). "Molecular targeting of the UDP-glucuronosyltransferase enzymes in high-eukaryotic translation initiation factor 4E refractory/relapsed acute myeloid leukemia patients: a randomized phase II trial of vismodegib, ribavirin with or without decitabine". Haematologica. 108 (11): 2946–2958. doi:10.3324/haematol.2023.282791. PMC 10620574. PMID 36951168. S2CID 257733013.
Zahreddine HA, Culjkovic-Kraljacic B, Assouline S, Gendron P, Romeo AA, Morris SJ, et al. (July 2014). "The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation". Nature. 511 (7507): 90–93. Bibcode:2014Natur.511...90Z. doi:10.1038/nature13283. PMC 4138053. PMID 24870236.
Alvarez D, Dieterich DT, Brau N, Moorehead L, Ball L, Sulkowski MS (October 2006). "Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons". Journal of Viral Hepatitis. 13 (10): 683–689. doi:10.1111/j.1365-2893.2006.00749.x. PMID 16970600. S2CID 21474337.
Bani-Sadr F, Carrat F, Pol S, Hor R, Rosenthal E, Goujard C, et al. (Anrs Hc02-Ribavic Study Team) (September 2005). "Risk factors for symptomatic mitochondrial toxicity in HIV/hepatitis C virus-coinfected patients during interferon plus ribavirin-based therapy". Journal of Acquired Immune Deficiency Syndromes. 40 (1): 47–52. doi:10.1097/01.qai.0000174649.51084.46. PMID 16123681. S2CID 9364536.
Graci JD, Cameron CE (January 2006). "Mechanisms of action of ribavirin against distinct viruses". Reviews in Medical Virology. 16 (1): 37–48. doi:10.1002/rmv.483. PMC 7169142. PMID 16287208.
Nyström K, Wanrooij PH, Waldenström J, Adamek L, Brunet S, Said J, et al. (October 2018). "Inosine Triphosphate Pyrophosphatase Dephosphorylates Ribavirin Triphosphate and Reduced Enzymatic Activity Potentiates Mutagenesis in Hepatitis C Virus". Journal of Virology. 92 (19): 01087–18. doi:10.1128/JVI.01087-18. PMC 6146798. PMID 30045981.
Ortega-Prieto AM, Sheldon J, Grande-Pérez A, Tejero H, Gregori J, Quer J, et al. (2013). Vartanian JP (ed.). "Extinction of hepatitis C virus by ribavirin in hepatoma cells involves lethal mutagenesis". PLOS ONE. 8 (8): e71039. Bibcode:2013PLoSO...871039O. doi:10.1371/journal.pone.0071039. PMC 3745404. PMID 23976977.
Crotty S, Cameron C, Andino R (February 2002). "Ribavirin's antiviral mechanism of action: lethal mutagenesis?". Journal of Molecular Medicine. 80 (2): 86–95. doi:10.1007/s00109-001-0308-0. PMID 11907645. S2CID 52851826.
Leyssen P, De Clercq E, Neyts J (April 2006). "The anti-yellow fever virus activity of ribavirin is independent of error-prone replication". Molecular Pharmacology. 69 (4): 1461–1467. doi:10.1124/mol.105.020057. PMID 16421290. S2CID 8158590.
Kentsis A, Topisirovic I, Culjkovic B, Shao L, Borden KL (December 2004). "Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap". Proceedings of the National Academy of Sciences of the United States of America. 101 (52): 18105–18110. Bibcode:2004PNAS..10118105K. doi:10.1073/pnas.0406927102. PMC 539790. PMID 15601771.
Kentsis A, Volpon L, Topisirovic I, Soll CE, Culjkovic B, Shao L, et al. (December 2005). "Further evidence that ribavirin interacts with eIF4E". RNA. 11 (12): 1762–1766. doi:10.1261/rna.2238705. PMC 1370864. PMID 16251386.
Volpon L, Osborne MJ, Zahreddine H, Romeo AA, Borden KL (May 2013). "Conformational changes induced in the eukaryotic translation initiation factor eIF4E by a clinically relevant inhibitor, ribavirin triphosphate". Biochemical and Biophysical Research Communications. 434 (3): 614–619. doi:10.1016/j.bbrc.2013.03.125. PMC 3659399. PMID 23583375.
Smee DF, Matthews TR (July 1986). "Metabolism of ribavirin in respiratory syncytial virus-infected and uninfected cells". Antimicrobial Agents and Chemotherapy. 30 (1): 117–121. doi:10.1128/AAC.30.1.117. PMC 176447. PMID 3752974.
Page T, Connor JD (January 1990). "The metabolism of ribavirin in erythrocytes and nucleated cells". The International Journal of Biochemistry. 22 (4): 379–383. doi:10.1016/0020-711X(90)90140-X. PMID 2159925.
Pettersson F, Yau C, Dobocan MC, Culjkovic-Kraljacic B, Retrouvey H, Puckett R, et al. (May 2011). "Ribavirin treatment effects on breast cancers overexpressing eIF4E, a biomarker with prognostic specificity for luminal B-type breast cancer". Clinical Cancer Research. 17 (9): 2874–2884. doi:10.1158/1078-0432.CCR-10-2334. PMC 3086959. PMID 21415224.
Bollmann F, Fechir K, Nowag S, Koch K, Art J, Kleinert H, et al. (April 2013). "Human inducible nitric oxide synthase (iNOS) expression depends on chromosome region maintenance 1 (CRM1)- and eukaryotic translation initiation factor 4E (elF4E)-mediated nucleocytoplasmic mRNA transport". Nitric Oxide. 30: 49–59. doi:10.1016/j.niox.2013.02.083. PMID 23471078.
Shi F, Len Y, Gong Y, Shi R, Yang X, Naren D, et al. (2015-08-28). Eaves CJ (ed.). "Ribavirin Inhibits the Activity of mTOR/eIF4E, ERK/Mnk1/eIF4E Signaling Pathway and Synergizes with Tyrosine Kinase Inhibitor Imatinib to Impair Bcr-Abl Mediated Proliferation and Apoptosis in Ph+ Leukemia". PLOS ONE. 10 (8): e0136746. Bibcode:2015PLoSO..1036746S. doi:10.1371/journal.pone.0136746. PMC 4552648. PMID 26317515.
Zismanov V, Attar-Schneider O, Lishner M, Heffez Aizenfeld R, Tartakover Matalon S, Drucker L (February 2015). "Multiple myeloma proteostasis can be targeted via translation initiation factor eIF4E". International Journal of Oncology. 46 (2): 860–870. doi:10.3892/ijo.2014.2774. PMID 25422161.
Dai D, Chen H, Tang J, Tang Y (January 2017). "Inhibition of mTOR/eIF4E by anti-viral drug ribavirin effectively enhances the effects of paclitaxel in oral tongue squamous cell carcinoma". Biochemical and Biophysical Research Communications. 482 (4): 1259–1264. doi:10.1016/j.bbrc.2016.12.025. PMID 27932243.
Volpin F, Casaos J, Sesen J, Mangraviti A, Choi J, Gorelick N, et al. (May 2017). "Use of an anti-viral drug, Ribavirin, as an anti-glioblastoma therapeutic". Oncogene. 36 (21): 3037–3047. doi:10.1038/onc.2016.457. PMID 27941882. S2CID 21655102.
Wang G, Li Z, Li Z, Huang Y, Mao X, Xu C, et al. (December 2017). "Targeting eIF4E inhibits growth, survival and angiogenesis in retinoblastoma and enhances efficacy of chemotherapy". Biomedicine & Pharmacotherapy. 96: 750–756. doi:10.1016/j.biopha.2017.10.034. PMID 29049978.
Xi C, Wang L, Yu J, Ye H, Cao L, Gong Z (September 2018). "Inhibition of eukaryotic translation initiation factor 4E is effective against chemo-resistance in colon and cervical cancer". Biochemical and Biophysical Research Communications. 503 (4): 2286–2292. doi:10.1016/j.bbrc.2018.06.150. PMID 29959920. S2CID 49634908.
Jin J, Xiang W, Wu S, Wang M, Xiao M, Deng A (March 2019). "Targeting eIF4E signaling with ribavirin as a sensitizing strategy for ovarian cancer". Biochemical and Biophysical Research Communications. 510 (4): 580–586. doi:10.1016/j.bbrc.2019.01.117. PMID 30739792. S2CID 73419809.
Urtishak KA, Wang LS, Culjkovic-Kraljacic B, Davenport JW, Porazzi P, Vincent TL, et al. (March 2019). "Targeting EIF4E signaling with ribavirin in infant acute lymphoblastic leukemia". Oncogene. 38 (13): 2241–2262. doi:10.1038/s41388-018-0567-7. PMC 6440839. PMID 30478448.
Volpon L, Culjkovic-Kraljacic B, Osborne MJ, Ramteke A, Sun Q, Niesman A, et al. (May 2016). "Importin 8 mediates m7G cap-sensitive nuclear import of the eukaryotic translation initiation factor eIF4E". Proceedings of the National Academy of Sciences of the United States of America. 113 (19): 5263–5268. Bibcode:2016PNAS..113.5263V. doi:10.1073/pnas.1524291113. PMC 4868427. PMID 27114554.
Snell NJ (August 2001). "Ribavirin--current status of a broad spectrum antiviral agent". Expert Opinion on Pharmacotherapy. 2 (8): 1317–1324. doi:10.1517/14656566.2.8.1317. PMID 11585000. S2CID 46564870.
Sidwell RW, Huffman JH, Khare GP, Allen LB, Witkowski JT, Robins RK (August 1972). "Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide". Science. 177 (4050): 705–706. Bibcode:1972Sci...177..705S. doi:10.1126/science.177.4050.705. PMID 4340949. S2CID 43106875.
Leung CW, Kwan YW, Ko PW, Chiu SS, Loung PY, Fong NC, et al. (June 2004). "Severe acute respiratory syndrome among children". Pediatrics. 113 (6): e535–e543. doi:10.1542/peds.113.6.e535. PMID 15173534.
Crowe D (February 2020). "SARS - Sterioid and Ribavirin Scandal". Unpublished Preprint. doi:10.13140/RG.2.2.25308.74881 – via researchgate.net. Author died before publication
Witkowski JT, Robins RK, Khare GP, Sidwell RW (August 1973). "Synthesis and antiviral activity of 1,2,4-triazole-3-thiocarboxamide and 1,2,4-triazole-3-carboxamidine ribonucleosides". Journal of Medicinal Chemistry. 16 (8): 935–937. doi:10.1021/jm00266a014. PMID 4355593.
Sidwell RW, Bailey KW, Wong MH, Barnard DL, Smee DF (October 2005). "In vitro and in vivo influenza virus-inhibitory effects of viramidine". Antiviral Research. 68 (1): 10–17. doi:10.1016/j.antiviral.2005.06.003. PMID 16087250.

drugs.com

"Ribavirin". The American Society of Health-System Pharmacists. Archived from the original on 20 December 2016. Retrieved 8 December 2016.
"Copegus: Package Insert". Drugs.com. 2023-03-27. Retrieved 2024-01-19.

fda.gov

nctr-crs.fda.gov

"FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA. Retrieved 22 Oct 2023.

accessdata.fda.gov

"Copedgus" (PDF). FDA.gov. Archived (PDF) from the original on 3 November 2014. Retrieved 16 April 2017.

handle.net

hdl.handle.net

World Health Organization (2009). Stuart MC, Kouimtzi M, Hill SR (eds.). WHO Model Formulary 2008. World Health Organization. p. 177. hdl:10665/44053. ISBN 9789241547659.
World Health Organization (2019). World Health Organization model list of essential medicines: 21st list 2019. Geneva: World Health Organization. hdl:10665/325771. WHO/MVP/EMP/IAU/2019.06. License: CC BY-NC-SA 3.0 IGO.

harvard.edu

ui.adsabs.harvard.edu

Zahreddine HA, Culjkovic-Kraljacic B, Assouline S, Gendron P, Romeo AA, Morris SJ, et al. (July 2014). "The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation". Nature. 511 (7507): 90–93. Bibcode:2014Natur.511...90Z. doi:10.1038/nature13283. PMC 4138053. PMID 24870236.
Ortega-Prieto AM, Sheldon J, Grande-Pérez A, Tejero H, Gregori J, Quer J, et al. (2013). Vartanian JP (ed.). "Extinction of hepatitis C virus by ribavirin in hepatoma cells involves lethal mutagenesis". PLOS ONE. 8 (8): e71039. Bibcode:2013PLoSO...871039O. doi:10.1371/journal.pone.0071039. PMC 3745404. PMID 23976977.
Kentsis A, Topisirovic I, Culjkovic B, Shao L, Borden KL (December 2004). "Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap". Proceedings of the National Academy of Sciences of the United States of America. 101 (52): 18105–18110. Bibcode:2004PNAS..10118105K. doi:10.1073/pnas.0406927102. PMC 539790. PMID 15601771.
Shi F, Len Y, Gong Y, Shi R, Yang X, Naren D, et al. (2015-08-28). Eaves CJ (ed.). "Ribavirin Inhibits the Activity of mTOR/eIF4E, ERK/Mnk1/eIF4E Signaling Pathway and Synergizes with Tyrosine Kinase Inhibitor Imatinib to Impair Bcr-Abl Mediated Proliferation and Apoptosis in Ph+ Leukemia". PLOS ONE. 10 (8): e0136746. Bibcode:2015PLoSO..1036746S. doi:10.1371/journal.pone.0136746. PMC 4552648. PMID 26317515.
Volpon L, Culjkovic-Kraljacic B, Osborne MJ, Ramteke A, Sun Q, Niesman A, et al. (May 2016). "Importin 8 mediates m7G cap-sensitive nuclear import of the eukaryotic translation initiation factor eIF4E". Proceedings of the National Academy of Sciences of the United States of America. 113 (19): 5263–5268. Bibcode:2016PNAS..113.5263V. doi:10.1073/pnas.1524291113. PMC 4868427. PMID 27114554.
Sidwell RW, Huffman JH, Khare GP, Allen LB, Witkowski JT, Robins RK (August 1972). "Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide". Science. 177 (4050): 705–706. Bibcode:1972Sci...177..705S. doi:10.1126/science.177.4050.705. PMID 4340949. S2CID 43106875.

in.gov.br

Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.

medscape.com

reference.medscape.com

"Rebetol, Ribasphere (ribavirin) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Archived from the original on 28 February 2014. Retrieved 23 February 2014.

news-medical.net

"Ribavirin History". News-Medical.net. 12 April 2010. Archived from the original on 2016-03-02. Retrieved 2016-02-19.

nih.gov

pubmed.ncbi.nlm.nih.gov

Paeshuyse J, Dallmeier K, Neyts J (December 2011). "Ribavirin for the treatment of chronic hepatitis C virus infection: a review of the proposed mechanisms of action". Current Opinion in Virology. 1 (6): 590–598. doi:10.1016/j.coviro.2011.10.030. PMID 22440916.
Flori N, Funakoshi N, Duny Y, Valats JC, Bismuth M, Christophorou D, et al. (March 2013). "Pegylated interferon-α2a and ribavirin versus pegylated interferon-α2b and ribavirin in chronic hepatitis C : a meta-analysis". Drugs. 73 (3): 263–277. doi:10.1007/s40265-013-0027-1. PMID 23436591. S2CID 46334977.
Druyts E, Thorlund K, Wu P, Kanters S, Yaya S, Cooper CL, et al. (April 2013). "Efficacy and safety of pegylated interferon alfa-2a or alfa-2b plus ribavirin for the treatment of chronic hepatitis C in children and adolescents: a systematic review and meta-analysis". Clinical Infectious Diseases. 56 (7): 961–967. doi:10.1093/cid/cis1031. PMID 23243171.
Zeuzem S, Poordad F (July 2010). "Pegylated-interferon plus ribavirin therapy in the treatment of CHC: individualization of treatment duration according to on-treatment virologic response". Current Medical Research and Opinion. 26 (7): 1733–1743. doi:10.1185/03007995.2010.487038. PMID 20482242. S2CID 206965239.
Zhu Q, Li N, Han Q, Zhang P, Yang C, Zeng X, et al. (June 2013). "Statin therapy improves response to interferon alfa and ribavirin in chronic hepatitis C: a systematic review and meta-analysis". Antiviral Research. 98 (3): 373–379. doi:10.1016/j.antiviral.2013.04.009. PMID 23603497.
Chung RT, Ghany MG, Kim AY, Marks KM, Naggie S, Vargas HE, et al. (AASLD-IDSA HCV Guidance Panel) (October 2018). "Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection". Clinical Infectious Diseases. 67 (10): 1477–1492. doi:10.1093/cid/ciy585. PMC 7190892. PMID 30215672.
Pawlotsky J, Negro F, Aghemo A, Berenguer M, Dalgard O, Dusheiko G, et al. (August 2018). "EASL Recommendations on Treatment of Hepatitis C 2018". Journal of Hepatology. 69 (2): 461–511. doi:10.1016/j.jhep.2018.03.026. PMID 29650333.
Ascioglu S, Leblebicioglu H, Vahaboglu H, Chan KA (June 2011). "Ribavirin for patients with Crimean-Congo haemorrhagic fever: a systematic review and meta-analysis". The Journal of Antimicrobial Chemotherapy. 66 (6): 1215–1222. doi:10.1093/jac/dkr136. PMID 21482564.
Bausch DG, Hadi CM, Khan SH, Lertora JJ (December 2010). "Review of the literature and proposed guidelines for the use of oral ribavirin as postexposure prophylaxis for Lassa fever". Clinical Infectious Diseases. 51 (12): 1435–1441. doi:10.1086/657315. PMC 7107935. PMID 21058912.
Soares-Weiser K, Thomas S, Thomson G, Garner P (July 2010). "Ribavirin for Crimean-Congo hemorrhagic fever: systematic review and meta-analysis". BMC Infectious Diseases. 10: 207. doi:10.1186/1471-2334-10-207. PMC 2912908. PMID 20626907.
Goeijenbier M, van Kampen JJ, Reusken CB, Koopmans MP, van Gorp EC (November 2014). "Ebola virus disease: a review on epidemiology, symptoms, treatment and pathogenesis". The Netherlands Journal of Medicine. 72 (9): 442–448. PMID 25387613. Archived from the original on 2014-11-29.
Ventre K, Randolph AG (January 2007). Ventre K (ed.). "Ribavirin for respiratory syncytial virus infection of the lower respiratory tract in infants and young children". The Cochrane Database of Systematic Reviews (1): CD000181. doi:10.1002/14651858.CD000181.pub3. PMID 17253446.
Hemachudha T, Ugolini G, Wacharapluesadee S, Sungkarat W, Shuangshoti S, Laothamatas J (May 2013). "Human rabies: neuropathogenesis, diagnosis, and management". The Lancet. Neurology. 12 (5): 498–513. doi:10.1016/S1474-4422(13)70038-3. PMID 23602163. S2CID 1798889.
Elia G, Belloli C, Cirone F, Lucente MS, Caruso M, Martella V, et al. (February 2008). "In vitro efficacy of ribavirin against canine distemper virus". Antiviral Research. 77 (2): 108–113. doi:10.1016/j.antiviral.2007.09.004. PMID 17949825.
Baker RO, Bray M, Huggins JW (January 2003). "Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections". Antiviral Research. 57 (1–2): 13–23. doi:10.1016/S0166-3542(02)00196-1. PMC 9533837. PMID 12615299.
Bierman SM, Kirkpatrick W, Fernandez H (1981). "Clinical efficacy of ribavirin in the treatment of genital herpes simplex virus infection". Chemotherapy. 27 (2): 139–145. doi:10.1159/000237969. PMID 7009087.
Pancheva SN (September 1991). "Potentiating effect of ribavirin on the anti-herpes activity of acyclovir". Antiviral Research. 16 (2): 151–161. doi:10.1016/0166-3542(91)90021-I. PMID 1665959.
Kast RE (November–December 2002). "Ribavirin in cancer immunotherapies: controlling nitric oxide helps generate cytotoxic lymphocyte". Cancer Biology & Therapy. 1 (6): 626–630. doi:10.4161/cbt.310. PMID 12642684. S2CID 24010404.
Borden KL, Culjkovic-Kraljacic B (October 2010). "Ribavirin as an anti-cancer therapy: acute myeloid leukemia and beyond?". Leukemia & Lymphoma. 51 (10): 1805–1815. doi:10.3109/10428194.2010.496506. PMC 2950216. PMID 20629523.
Dunn LA, Fury MG, Sherman EJ, Ho AA, Katabi N, Haque SS, et al. (February 2018). "Phase I study of induction chemotherapy with afatinib, ribavirin, and weekly carboplatin and paclitaxel for stage IVA/IVB human papillomavirus-associated oropharyngeal squamous cell cancer". Head & Neck. 40 (2): 233–241. doi:10.1002/hed.24938. PMC 6760238. PMID 28963790.
Burman B, Drutman SB, Fury MG, Wong RJ, Katabi N, Ho AL, et al. (May 2022). "Pharmacodynamic and therapeutic pilot studies of single-agent ribavirin in patients with human papillomavirus-related malignancies". Oral Oncology. 128: 105806. doi:10.1016/j.oraloncology.2022.105806. PMC 9788648. PMID 35339025.
Assouline S, Culjkovic B, Cocolakis E, Rousseau C, Beslu N, Amri A, et al. (July 2009). "Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin". Blood. 114 (2): 257–260. doi:10.1182/blood-2009-02-205153. PMID 19433856. S2CID 28957125.
Assouline S, Culjkovic-Kraljacic B, Bergeron J, Caplan S, Cocolakis E, Lambert C, et al. (January 2015). "A phase I trial of ribavirin and low-dose cytarabine for the treatment of relapsed and refractory acute myeloid leukemia with elevated eIF4E". Haematologica. 100 (1): e7–e9. doi:10.3324/haematol.2014.111245. PMC 4281321. PMID 25425688.
Assouline S, Gasiorek J, Bergeron J, Lambert C, Culjkovic-Kraljacic B, Cocolakis E, et al. (March 2023). "Molecular targeting of the UDP-glucuronosyltransferase enzymes in high-eukaryotic translation initiation factor 4E refractory/relapsed acute myeloid leukemia patients: a randomized phase II trial of vismodegib, ribavirin with or without decitabine". Haematologica. 108 (11): 2946–2958. doi:10.3324/haematol.2023.282791. PMC 10620574. PMID 36951168. S2CID 257733013.
Zahreddine HA, Culjkovic-Kraljacic B, Assouline S, Gendron P, Romeo AA, Morris SJ, et al. (July 2014). "The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation". Nature. 511 (7507): 90–93. Bibcode:2014Natur.511...90Z. doi:10.1038/nature13283. PMC 4138053. PMID 24870236.
Alvarez D, Dieterich DT, Brau N, Moorehead L, Ball L, Sulkowski MS (October 2006). "Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons". Journal of Viral Hepatitis. 13 (10): 683–689. doi:10.1111/j.1365-2893.2006.00749.x. PMID 16970600. S2CID 21474337.
Bani-Sadr F, Carrat F, Pol S, Hor R, Rosenthal E, Goujard C, et al. (Anrs Hc02-Ribavic Study Team) (September 2005). "Risk factors for symptomatic mitochondrial toxicity in HIV/hepatitis C virus-coinfected patients during interferon plus ribavirin-based therapy". Journal of Acquired Immune Deficiency Syndromes. 40 (1): 47–52. doi:10.1097/01.qai.0000174649.51084.46. PMID 16123681. S2CID 9364536.
Graci JD, Cameron CE (January 2006). "Mechanisms of action of ribavirin against distinct viruses". Reviews in Medical Virology. 16 (1): 37–48. doi:10.1002/rmv.483. PMC 7169142. PMID 16287208.
Nyström K, Wanrooij PH, Waldenström J, Adamek L, Brunet S, Said J, et al. (October 2018). "Inosine Triphosphate Pyrophosphatase Dephosphorylates Ribavirin Triphosphate and Reduced Enzymatic Activity Potentiates Mutagenesis in Hepatitis C Virus". Journal of Virology. 92 (19): 01087–18. doi:10.1128/JVI.01087-18. PMC 6146798. PMID 30045981.
Ortega-Prieto AM, Sheldon J, Grande-Pérez A, Tejero H, Gregori J, Quer J, et al. (2013). Vartanian JP (ed.). "Extinction of hepatitis C virus by ribavirin in hepatoma cells involves lethal mutagenesis". PLOS ONE. 8 (8): e71039. Bibcode:2013PLoSO...871039O. doi:10.1371/journal.pone.0071039. PMC 3745404. PMID 23976977.
Crotty S, Cameron C, Andino R (February 2002). "Ribavirin's antiviral mechanism of action: lethal mutagenesis?". Journal of Molecular Medicine. 80 (2): 86–95. doi:10.1007/s00109-001-0308-0. PMID 11907645. S2CID 52851826.
Leyssen P, De Clercq E, Neyts J (April 2006). "The anti-yellow fever virus activity of ribavirin is independent of error-prone replication". Molecular Pharmacology. 69 (4): 1461–1467. doi:10.1124/mol.105.020057. PMID 16421290. S2CID 8158590.
Kentsis A, Topisirovic I, Culjkovic B, Shao L, Borden KL (December 2004). "Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap". Proceedings of the National Academy of Sciences of the United States of America. 101 (52): 18105–18110. Bibcode:2004PNAS..10118105K. doi:10.1073/pnas.0406927102. PMC 539790. PMID 15601771.
Kentsis A, Volpon L, Topisirovic I, Soll CE, Culjkovic B, Shao L, et al. (December 2005). "Further evidence that ribavirin interacts with eIF4E". RNA. 11 (12): 1762–1766. doi:10.1261/rna.2238705. PMC 1370864. PMID 16251386.
Volpon L, Osborne MJ, Zahreddine H, Romeo AA, Borden KL (May 2013). "Conformational changes induced in the eukaryotic translation initiation factor eIF4E by a clinically relevant inhibitor, ribavirin triphosphate". Biochemical and Biophysical Research Communications. 434 (3): 614–619. doi:10.1016/j.bbrc.2013.03.125. PMC 3659399. PMID 23583375.
Smee DF, Matthews TR (July 1986). "Metabolism of ribavirin in respiratory syncytial virus-infected and uninfected cells". Antimicrobial Agents and Chemotherapy. 30 (1): 117–121. doi:10.1128/AAC.30.1.117. PMC 176447. PMID 3752974.
Page T, Connor JD (January 1990). "The metabolism of ribavirin in erythrocytes and nucleated cells". The International Journal of Biochemistry. 22 (4): 379–383. doi:10.1016/0020-711X(90)90140-X. PMID 2159925.
Pettersson F, Yau C, Dobocan MC, Culjkovic-Kraljacic B, Retrouvey H, Puckett R, et al. (May 2011). "Ribavirin treatment effects on breast cancers overexpressing eIF4E, a biomarker with prognostic specificity for luminal B-type breast cancer". Clinical Cancer Research. 17 (9): 2874–2884. doi:10.1158/1078-0432.CCR-10-2334. PMC 3086959. PMID 21415224.
Bollmann F, Fechir K, Nowag S, Koch K, Art J, Kleinert H, et al. (April 2013). "Human inducible nitric oxide synthase (iNOS) expression depends on chromosome region maintenance 1 (CRM1)- and eukaryotic translation initiation factor 4E (elF4E)-mediated nucleocytoplasmic mRNA transport". Nitric Oxide. 30: 49–59. doi:10.1016/j.niox.2013.02.083. PMID 23471078.
Shi F, Len Y, Gong Y, Shi R, Yang X, Naren D, et al. (2015-08-28). Eaves CJ (ed.). "Ribavirin Inhibits the Activity of mTOR/eIF4E, ERK/Mnk1/eIF4E Signaling Pathway and Synergizes with Tyrosine Kinase Inhibitor Imatinib to Impair Bcr-Abl Mediated Proliferation and Apoptosis in Ph+ Leukemia". PLOS ONE. 10 (8): e0136746. Bibcode:2015PLoSO..1036746S. doi:10.1371/journal.pone.0136746. PMC 4552648. PMID 26317515.
Zismanov V, Attar-Schneider O, Lishner M, Heffez Aizenfeld R, Tartakover Matalon S, Drucker L (February 2015). "Multiple myeloma proteostasis can be targeted via translation initiation factor eIF4E". International Journal of Oncology. 46 (2): 860–870. doi:10.3892/ijo.2014.2774. PMID 25422161.
Dai D, Chen H, Tang J, Tang Y (January 2017). "Inhibition of mTOR/eIF4E by anti-viral drug ribavirin effectively enhances the effects of paclitaxel in oral tongue squamous cell carcinoma". Biochemical and Biophysical Research Communications. 482 (4): 1259–1264. doi:10.1016/j.bbrc.2016.12.025. PMID 27932243.
Volpin F, Casaos J, Sesen J, Mangraviti A, Choi J, Gorelick N, et al. (May 2017). "Use of an anti-viral drug, Ribavirin, as an anti-glioblastoma therapeutic". Oncogene. 36 (21): 3037–3047. doi:10.1038/onc.2016.457. PMID 27941882. S2CID 21655102.
Wang G, Li Z, Li Z, Huang Y, Mao X, Xu C, et al. (December 2017). "Targeting eIF4E inhibits growth, survival and angiogenesis in retinoblastoma and enhances efficacy of chemotherapy". Biomedicine & Pharmacotherapy. 96: 750–756. doi:10.1016/j.biopha.2017.10.034. PMID 29049978.
Xi C, Wang L, Yu J, Ye H, Cao L, Gong Z (September 2018). "Inhibition of eukaryotic translation initiation factor 4E is effective against chemo-resistance in colon and cervical cancer". Biochemical and Biophysical Research Communications. 503 (4): 2286–2292. doi:10.1016/j.bbrc.2018.06.150. PMID 29959920. S2CID 49634908.
Jin J, Xiang W, Wu S, Wang M, Xiao M, Deng A (March 2019). "Targeting eIF4E signaling with ribavirin as a sensitizing strategy for ovarian cancer". Biochemical and Biophysical Research Communications. 510 (4): 580–586. doi:10.1016/j.bbrc.2019.01.117. PMID 30739792. S2CID 73419809.
Urtishak KA, Wang LS, Culjkovic-Kraljacic B, Davenport JW, Porazzi P, Vincent TL, et al. (March 2019). "Targeting EIF4E signaling with ribavirin in infant acute lymphoblastic leukemia". Oncogene. 38 (13): 2241–2262. doi:10.1038/s41388-018-0567-7. PMC 6440839. PMID 30478448.
Volpon L, Culjkovic-Kraljacic B, Osborne MJ, Ramteke A, Sun Q, Niesman A, et al. (May 2016). "Importin 8 mediates m7G cap-sensitive nuclear import of the eukaryotic translation initiation factor eIF4E". Proceedings of the National Academy of Sciences of the United States of America. 113 (19): 5263–5268. Bibcode:2016PNAS..113.5263V. doi:10.1073/pnas.1524291113. PMC 4868427. PMID 27114554.
Snell NJ (August 2001). "Ribavirin--current status of a broad spectrum antiviral agent". Expert Opinion on Pharmacotherapy. 2 (8): 1317–1324. doi:10.1517/14656566.2.8.1317. PMID 11585000. S2CID 46564870.
Sidwell RW, Huffman JH, Khare GP, Allen LB, Witkowski JT, Robins RK (August 1972). "Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide". Science. 177 (4050): 705–706. Bibcode:1972Sci...177..705S. doi:10.1126/science.177.4050.705. PMID 4340949. S2CID 43106875.
Koren G, King S, Knowles S, Phillips E (May 2003). "Ribavirin in the treatment of SARS: A new trick for an old drug?". CMAJ. 168 (10): 1289–1292. PMC 154189. PMID 12743076.
Leung CW, Kwan YW, Ko PW, Chiu SS, Loung PY, Fong NC, et al. (June 2004). "Severe acute respiratory syndrome among children". Pediatrics. 113 (6): e535–e543. doi:10.1542/peds.113.6.e535. PMID 15173534.
Witkowski JT, Robins RK, Khare GP, Sidwell RW (August 1973). "Synthesis and antiviral activity of 1,2,4-triazole-3-thiocarboxamide and 1,2,4-triazole-3-carboxamidine ribonucleosides". Journal of Medicinal Chemistry. 16 (8): 935–937. doi:10.1021/jm00266a014. PMID 4355593.
Sidwell RW, Bailey KW, Wong MH, Barnard DL, Smee DF (October 2005). "In vitro and in vivo influenza virus-inhibitory effects of viramidine". Antiviral Research. 68 (1): 10–17. doi:10.1016/j.antiviral.2005.06.003. PMID 16087250.

ncbi.nlm.nih.gov

Chung RT, Ghany MG, Kim AY, Marks KM, Naggie S, Vargas HE, et al. (AASLD-IDSA HCV Guidance Panel) (October 2018). "Hepatitis C Guidance 2018 Update: AASLD-IDSA Recommendations for Testing, Managing, and Treating Hepatitis C Virus Infection". Clinical Infectious Diseases. 67 (10): 1477–1492. doi:10.1093/cid/ciy585. PMC 7190892. PMID 30215672.
Bausch DG, Hadi CM, Khan SH, Lertora JJ (December 2010). "Review of the literature and proposed guidelines for the use of oral ribavirin as postexposure prophylaxis for Lassa fever". Clinical Infectious Diseases. 51 (12): 1435–1441. doi:10.1086/657315. PMC 7107935. PMID 21058912.
Soares-Weiser K, Thomas S, Thomson G, Garner P (July 2010). "Ribavirin for Crimean-Congo hemorrhagic fever: systematic review and meta-analysis". BMC Infectious Diseases. 10: 207. doi:10.1186/1471-2334-10-207. PMC 2912908. PMID 20626907.
Baker RO, Bray M, Huggins JW (January 2003). "Potential antiviral therapeutics for smallpox, monkeypox and other orthopoxvirus infections". Antiviral Research. 57 (1–2): 13–23. doi:10.1016/S0166-3542(02)00196-1. PMC 9533837. PMID 12615299.
Borden KL, Culjkovic-Kraljacic B (October 2010). "Ribavirin as an anti-cancer therapy: acute myeloid leukemia and beyond?". Leukemia & Lymphoma. 51 (10): 1805–1815. doi:10.3109/10428194.2010.496506. PMC 2950216. PMID 20629523.
Dunn LA, Fury MG, Sherman EJ, Ho AA, Katabi N, Haque SS, et al. (February 2018). "Phase I study of induction chemotherapy with afatinib, ribavirin, and weekly carboplatin and paclitaxel for stage IVA/IVB human papillomavirus-associated oropharyngeal squamous cell cancer". Head & Neck. 40 (2): 233–241. doi:10.1002/hed.24938. PMC 6760238. PMID 28963790.
Burman B, Drutman SB, Fury MG, Wong RJ, Katabi N, Ho AL, et al. (May 2022). "Pharmacodynamic and therapeutic pilot studies of single-agent ribavirin in patients with human papillomavirus-related malignancies". Oral Oncology. 128: 105806. doi:10.1016/j.oraloncology.2022.105806. PMC 9788648. PMID 35339025.
Assouline S, Culjkovic-Kraljacic B, Bergeron J, Caplan S, Cocolakis E, Lambert C, et al. (January 2015). "A phase I trial of ribavirin and low-dose cytarabine for the treatment of relapsed and refractory acute myeloid leukemia with elevated eIF4E". Haematologica. 100 (1): e7–e9. doi:10.3324/haematol.2014.111245. PMC 4281321. PMID 25425688.
Assouline S, Gasiorek J, Bergeron J, Lambert C, Culjkovic-Kraljacic B, Cocolakis E, et al. (March 2023). "Molecular targeting of the UDP-glucuronosyltransferase enzymes in high-eukaryotic translation initiation factor 4E refractory/relapsed acute myeloid leukemia patients: a randomized phase II trial of vismodegib, ribavirin with or without decitabine". Haematologica. 108 (11): 2946–2958. doi:10.3324/haematol.2023.282791. PMC 10620574. PMID 36951168. S2CID 257733013.
Zahreddine HA, Culjkovic-Kraljacic B, Assouline S, Gendron P, Romeo AA, Morris SJ, et al. (July 2014). "The sonic hedgehog factor GLI1 imparts drug resistance through inducible glucuronidation". Nature. 511 (7507): 90–93. Bibcode:2014Natur.511...90Z. doi:10.1038/nature13283. PMC 4138053. PMID 24870236.
Graci JD, Cameron CE (January 2006). "Mechanisms of action of ribavirin against distinct viruses". Reviews in Medical Virology. 16 (1): 37–48. doi:10.1002/rmv.483. PMC 7169142. PMID 16287208.
Nyström K, Wanrooij PH, Waldenström J, Adamek L, Brunet S, Said J, et al. (October 2018). "Inosine Triphosphate Pyrophosphatase Dephosphorylates Ribavirin Triphosphate and Reduced Enzymatic Activity Potentiates Mutagenesis in Hepatitis C Virus". Journal of Virology. 92 (19): 01087–18. doi:10.1128/JVI.01087-18. PMC 6146798. PMID 30045981.
Ortega-Prieto AM, Sheldon J, Grande-Pérez A, Tejero H, Gregori J, Quer J, et al. (2013). Vartanian JP (ed.). "Extinction of hepatitis C virus by ribavirin in hepatoma cells involves lethal mutagenesis". PLOS ONE. 8 (8): e71039. Bibcode:2013PLoSO...871039O. doi:10.1371/journal.pone.0071039. PMC 3745404. PMID 23976977.
Kentsis A, Topisirovic I, Culjkovic B, Shao L, Borden KL (December 2004). "Ribavirin suppresses eIF4E-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mRNA cap". Proceedings of the National Academy of Sciences of the United States of America. 101 (52): 18105–18110. Bibcode:2004PNAS..10118105K. doi:10.1073/pnas.0406927102. PMC 539790. PMID 15601771.
Kentsis A, Volpon L, Topisirovic I, Soll CE, Culjkovic B, Shao L, et al. (December 2005). "Further evidence that ribavirin interacts with eIF4E". RNA. 11 (12): 1762–1766. doi:10.1261/rna.2238705. PMC 1370864. PMID 16251386.
Volpon L, Osborne MJ, Zahreddine H, Romeo AA, Borden KL (May 2013). "Conformational changes induced in the eukaryotic translation initiation factor eIF4E by a clinically relevant inhibitor, ribavirin triphosphate". Biochemical and Biophysical Research Communications. 434 (3): 614–619. doi:10.1016/j.bbrc.2013.03.125. PMC 3659399. PMID 23583375.
Smee DF, Matthews TR (July 1986). "Metabolism of ribavirin in respiratory syncytial virus-infected and uninfected cells". Antimicrobial Agents and Chemotherapy. 30 (1): 117–121. doi:10.1128/AAC.30.1.117. PMC 176447. PMID 3752974.
Pettersson F, Yau C, Dobocan MC, Culjkovic-Kraljacic B, Retrouvey H, Puckett R, et al. (May 2011). "Ribavirin treatment effects on breast cancers overexpressing eIF4E, a biomarker with prognostic specificity for luminal B-type breast cancer". Clinical Cancer Research. 17 (9): 2874–2884. doi:10.1158/1078-0432.CCR-10-2334. PMC 3086959. PMID 21415224.
Shi F, Len Y, Gong Y, Shi R, Yang X, Naren D, et al. (2015-08-28). Eaves CJ (ed.). "Ribavirin Inhibits the Activity of mTOR/eIF4E, ERK/Mnk1/eIF4E Signaling Pathway and Synergizes with Tyrosine Kinase Inhibitor Imatinib to Impair Bcr-Abl Mediated Proliferation and Apoptosis in Ph+ Leukemia". PLOS ONE. 10 (8): e0136746. Bibcode:2015PLoSO..1036746S. doi:10.1371/journal.pone.0136746. PMC 4552648. PMID 26317515.
Urtishak KA, Wang LS, Culjkovic-Kraljacic B, Davenport JW, Porazzi P, Vincent TL, et al. (March 2019). "Targeting EIF4E signaling with ribavirin in infant acute lymphoblastic leukemia". Oncogene. 38 (13): 2241–2262. doi:10.1038/s41388-018-0567-7. PMC 6440839. PMID 30478448.
Volpon L, Culjkovic-Kraljacic B, Osborne MJ, Ramteke A, Sun Q, Niesman A, et al. (May 2016). "Importin 8 mediates m7G cap-sensitive nuclear import of the eukaryotic translation initiation factor eIF4E". Proceedings of the National Academy of Sciences of the United States of America. 113 (19): 5263–5268. Bibcode:2016PNAS..113.5263V. doi:10.1073/pnas.1524291113. PMC 4868427. PMID 27114554.
Koren G, King S, Knowles S, Phillips E (May 2003). "Ribavirin in the treatment of SARS: A new trick for an old drug?". CMAJ. 168 (10): 1289–1292. PMC 154189. PMID 12743076.

njmonline.nl

Goeijenbier M, van Kampen JJ, Reusken CB, Koopmans MP, van Gorp EC (November 2014). "Ebola virus disease: a review on epidemiology, symptoms, treatment and pathogenesis". The Netherlands Journal of Medicine. 72 (9): 442–448. PMID 25387613. Archived from the original on 2014-11-29.

researchgate.net

Crowe D (February 2020). "SARS - Sterioid and Ribavirin Scandal". Unpublished Preprint. doi:10.13140/RG.2.2.25308.74881 – via researchgate.net. Author died before publication

rki.de

Steckbriefe seltener und importierter Infektionskrankheiten [Characteristics of rare and imported infectious diseases] (PDF). Berlin: Robert Koch Institute. 2006. ISBN 978-3-89606-095-2. Archived from the original (PDF) on 2011-09-29.

semanticscholar.org

api.semanticscholar.org

Flori N, Funakoshi N, Duny Y, Valats JC, Bismuth M, Christophorou D, et al. (March 2013). "Pegylated interferon-α2a and ribavirin versus pegylated interferon-α2b and ribavirin in chronic hepatitis C : a meta-analysis". Drugs. 73 (3): 263–277. doi:10.1007/s40265-013-0027-1. PMID 23436591. S2CID 46334977.
Zeuzem S, Poordad F (July 2010). "Pegylated-interferon plus ribavirin therapy in the treatment of CHC: individualization of treatment duration according to on-treatment virologic response". Current Medical Research and Opinion. 26 (7): 1733–1743. doi:10.1185/03007995.2010.487038. PMID 20482242. S2CID 206965239.
Hemachudha T, Ugolini G, Wacharapluesadee S, Sungkarat W, Shuangshoti S, Laothamatas J (May 2013). "Human rabies: neuropathogenesis, diagnosis, and management". The Lancet. Neurology. 12 (5): 498–513. doi:10.1016/S1474-4422(13)70038-3. PMID 23602163. S2CID 1798889.
Kast RE (November–December 2002). "Ribavirin in cancer immunotherapies: controlling nitric oxide helps generate cytotoxic lymphocyte". Cancer Biology & Therapy. 1 (6): 626–630. doi:10.4161/cbt.310. PMID 12642684. S2CID 24010404.
Assouline S, Culjkovic B, Cocolakis E, Rousseau C, Beslu N, Amri A, et al. (July 2009). "Molecular targeting of the oncogene eIF4E in acute myeloid leukemia (AML): a proof-of-principle clinical trial with ribavirin". Blood. 114 (2): 257–260. doi:10.1182/blood-2009-02-205153. PMID 19433856. S2CID 28957125.
Assouline S, Gasiorek J, Bergeron J, Lambert C, Culjkovic-Kraljacic B, Cocolakis E, et al. (March 2023). "Molecular targeting of the UDP-glucuronosyltransferase enzymes in high-eukaryotic translation initiation factor 4E refractory/relapsed acute myeloid leukemia patients: a randomized phase II trial of vismodegib, ribavirin with or without decitabine". Haematologica. 108 (11): 2946–2958. doi:10.3324/haematol.2023.282791. PMC 10620574. PMID 36951168. S2CID 257733013.
Alvarez D, Dieterich DT, Brau N, Moorehead L, Ball L, Sulkowski MS (October 2006). "Zidovudine use but not weight-based ribavirin dosing impacts anaemia during HCV treatment in HIV-infected persons". Journal of Viral Hepatitis. 13 (10): 683–689. doi:10.1111/j.1365-2893.2006.00749.x. PMID 16970600. S2CID 21474337.
Bani-Sadr F, Carrat F, Pol S, Hor R, Rosenthal E, Goujard C, et al. (Anrs Hc02-Ribavic Study Team) (September 2005). "Risk factors for symptomatic mitochondrial toxicity in HIV/hepatitis C virus-coinfected patients during interferon plus ribavirin-based therapy". Journal of Acquired Immune Deficiency Syndromes. 40 (1): 47–52. doi:10.1097/01.qai.0000174649.51084.46. PMID 16123681. S2CID 9364536.
Crotty S, Cameron C, Andino R (February 2002). "Ribavirin's antiviral mechanism of action: lethal mutagenesis?". Journal of Molecular Medicine. 80 (2): 86–95. doi:10.1007/s00109-001-0308-0. PMID 11907645. S2CID 52851826.
Leyssen P, De Clercq E, Neyts J (April 2006). "The anti-yellow fever virus activity of ribavirin is independent of error-prone replication". Molecular Pharmacology. 69 (4): 1461–1467. doi:10.1124/mol.105.020057. PMID 16421290. S2CID 8158590.
Volpin F, Casaos J, Sesen J, Mangraviti A, Choi J, Gorelick N, et al. (May 2017). "Use of an anti-viral drug, Ribavirin, as an anti-glioblastoma therapeutic". Oncogene. 36 (21): 3037–3047. doi:10.1038/onc.2016.457. PMID 27941882. S2CID 21655102.
Xi C, Wang L, Yu J, Ye H, Cao L, Gong Z (September 2018). "Inhibition of eukaryotic translation initiation factor 4E is effective against chemo-resistance in colon and cervical cancer". Biochemical and Biophysical Research Communications. 503 (4): 2286–2292. doi:10.1016/j.bbrc.2018.06.150. PMID 29959920. S2CID 49634908.
Jin J, Xiang W, Wu S, Wang M, Xiao M, Deng A (March 2019). "Targeting eIF4E signaling with ribavirin as a sensitizing strategy for ovarian cancer". Biochemical and Biophysical Research Communications. 510 (4): 580–586. doi:10.1016/j.bbrc.2019.01.117. PMID 30739792. S2CID 73419809.
Snell NJ (August 2001). "Ribavirin--current status of a broad spectrum antiviral agent". Expert Opinion on Pharmacotherapy. 2 (8): 1317–1324. doi:10.1517/14656566.2.8.1317. PMID 11585000. S2CID 46564870.
Sidwell RW, Huffman JH, Khare GP, Allen LB, Witkowski JT, Robins RK (August 1972). "Broad-spectrum antiviral activity of Virazole: 1-beta-D-ribofuranosyl-1,2,4-triazole-3-carboxamide". Science. 177 (4050): 705–706. Bibcode:1972Sci...177..705S. doi:10.1126/science.177.4050.705. PMID 4340949. S2CID 43106875.

tga.gov.au

ebs.tga.gov.au

"PRODUCT INFORMATION REBETOL (RIBAVIRIN) CAPSULES" (PDF). TGA eBusiness Services. Merck Sharp & Dohme (Australia) Pty Limited. 29 April 2013. Archived from the original on 16 August 2017. Retrieved 23 February 2014.

web.archive.org

"Ribavirin". The American Society of Health-System Pharmacists. Archived from the original on 20 December 2016. Retrieved 8 December 2016.
Anvisa (2023-03-31). "RDC Nº 784 - Listas de Substâncias Entorpecentes, Psicotrópicas, Precursoras e Outras sob Controle Especial" [Collegiate Board Resolution No. 784 - Lists of Narcotic, Psychotropic, Precursor, and Other Substances under Special Control] (in Brazilian Portuguese). Diário Oficial da União (published 2023-04-04). Archived from the original on 2023-08-03. Retrieved 2023-08-16.
"PRODUCT INFORMATION REBETOL (RIBAVIRIN) CAPSULES" (PDF). TGA eBusiness Services. Merck Sharp & Dohme (Australia) Pty Limited. 29 April 2013. Archived from the original on 16 August 2017. Retrieved 23 February 2014.
Fischer J, Ganellin CR (2006). Analogue-based Drug Discovery. John Wiley & Sons. p. 504. ISBN 9783527607495. Archived from the original on 2016-12-20.
"Rebetol, Ribasphere (ribavirin) dosing, indications, interactions, adverse effects, and more". Medscape Reference. WebMD. Archived from the original on 28 February 2014. Retrieved 23 February 2014.
Steckbriefe seltener und importierter Infektionskrankheiten [Characteristics of rare and imported infectious diseases] (PDF). Berlin: Robert Koch Institute. 2006. ISBN 978-3-89606-095-2. Archived from the original (PDF) on 2011-09-29.
Goeijenbier M, van Kampen JJ, Reusken CB, Koopmans MP, van Gorp EC (November 2014). "Ebola virus disease: a review on epidemiology, symptoms, treatment and pathogenesis". The Netherlands Journal of Medicine. 72 (9): 442–448. PMID 25387613. Archived from the original on 2014-11-29.
"Treatment | Lassa Fever | CDC". 2023-09-26. Archived from the original on 2023-09-26. Retrieved 2024-01-20.
"Copedgus" (PDF). FDA.gov. Archived (PDF) from the original on 3 November 2014. Retrieved 16 April 2017.
"Ribavirin History". News-Medical.net. 12 April 2010. Archived from the original on 2016-03-02. Retrieved 2016-02-19.